The Gut Microbial Bile Acid Modulation and Its Relevance to Digestive Health and Diseases
暂无分享,去创建一个
[1] J. Crawford,et al. Commensal microbiota from patients with inflammatory bowel disease produce genotoxic metabolites , 2022, Science.
[2] Karam R. Motawea,et al. Efficacy and safety of fecal microbiota transplant in irritable bowel syndrome: An update based on meta‐analysis of randomized control trials , 2022, Health science reports.
[3] Yousong Ding,et al. Methods of DNA Introduction for the Engineering of Commensal Microbes , 2022, Engineering Microbiology.
[4] A. Saghatelian,et al. Diet and feeding pattern modulate diurnal dynamics of the ileal microbiome and transcriptome , 2022, Cell reports.
[5] Ming-Shiang Wu,et al. Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson's Disease. , 2022, Journal of Parkinson's disease.
[6] K. Nie,et al. TGR5 Agonist INT-777 Alleviates Inflammatory Neurodegeneration in Parkinson’s Disease Mouse Model by Modulating Mitochondrial Dynamics in Microglia , 2022, Neuroscience.
[7] E. Pamer,et al. Microbiome-based therapeutics , 2022, Nature Reviews Microbiology.
[8] J. Hasty,et al. Intestinal transgene delivery with native E. coli chassis allows persistent physiological changes , 2021, Cell.
[9] D. O’Malley,et al. Aberrant Gut-To-Brain Signaling in Irritable Bowel Syndrome - The Role of Bile Acids , 2021, Frontiers in Endocrinology.
[10] Bangmao Wang,et al. Gut microbiota-derived short-chain fatty acids and colorectal cancer: Ready for clinical translation? , 2021, Cancer letters.
[11] Emily C. Gentry,et al. High-confidence structural annotation of metabolites absent from spectral libraries , 2021, Nature Biotechnology.
[12] Qin Liu,et al. Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome , 2021, Frontiers in Cellular and Infection Microbiology.
[13] P. Dorrestein,et al. Mass spectrometry-based metabolomics in microbiome investigations , 2021, Nature Reviews Microbiology.
[14] J. Keenan,et al. Concentrations of Fecal Bile Acids in Participants with Functional Gut Disorders and Healthy Controls , 2021, Metabolites.
[15] Emily C. Gentry,et al. A Synthesis-Based Reverse Metabolomics Approach for the Discovery of Chemical Structures from Humans and Animals. , 2021 .
[16] A. Sutton,et al. Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. , 2021, The Cochrane database of systematic reviews.
[17] Haojun Yang,et al. TGR5 protects against cholestatic liver disease via suppressing the NF-κB pathway and activating the Nrf2/HO-1 pathway , 2021, Annals of translational medicine.
[18] J. Wilkinson,et al. Irritable Bowel Syndrome: Questions and Answers for Effective Care. , 2021, American family physician.
[19] K. McVey Neufeld,et al. Animal models of visceral pain and the role of the microbiome , 2021, Neurobiology of pain.
[20] E. Chang,et al. Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism , 2021, Nature Reviews Gastroenterology & Hepatology.
[21] Kaichun Wu,et al. Fecal Microbiota Transplantation as Therapy for Treatment of Active Ulcerative Colitis: A Systematic Review and Meta-Analysis , 2021, Gastroenterology research and practice.
[22] Yongheng Chen,et al. Farnesoid X receptor (FXR): Structures and ligands , 2021, Computational and structural biotechnology journal.
[23] Mingxun Wang,et al. Chemical Proportionality within Molecular Networks. , 2021, Analytical chemistry.
[24] John C. Earls,et al. Gut microbiome pattern reflects healthy ageing and predicts survival in humans , 2021, Nature Metabolism.
[25] Guowang Xu,et al. Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry , 2021, Molecular neurodegeneration.
[26] Irving E. Vega,et al. Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson’s Disease , 2021, Metabolites.
[27] C. López-Otín,et al. Hallmarks of Health , 2020, Cell.
[28] Michele Biagioli,et al. Bile Acid Signaling in Inflammatory Bowel Diseases , 2020, Digestive Diseases and Sciences.
[29] Wei Wei,et al. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome , 2020, World journal of gastroenterology.
[30] J. Griffin,et al. Metabolomic Analysis in Inflammatory Bowel Disease: A Systematic Review. , 2020, Journal of Crohn's & colitis.
[31] S. Ishihara,et al. Molecular Mechanisms of Microbiota-Mediated Pathology in Irritable Bowel Syndrome , 2020, International journal of molecular sciences.
[32] F. Bishehsari,et al. Circadian rhythms and the gut microbiota: from the metabolic syndrome to cancer , 2020, Nature Reviews Endocrinology.
[33] C. Quince,et al. The pathophysiology of bile acid diarrhoea: differences in the colonic microbiome, metabolome and bile acids , 2020, Scientific Reports.
[34] Haiyang Xie,et al. A novel role for farnesoid X receptor in the bile acid‐mediated intestinal glucose homeostasis , 2020, Journal of cellular and molecular medicine.
[35] Krishna R. Kalari,et al. Longitudinal Multi-omics Reveals Subset-Specific Mechanisms Underlying Irritable Bowel Syndrome , 2020, Cell.
[36] M. Heitkemper,et al. Bile Acids and Microbiome Among Individuals With Irritable Bowel Syndrome and Healthy Volunteers , 2020, Biological research for nursing.
[37] Emmanuel O. Elijah,et al. Paroxetine Administration Affects Microbiota and Bile Acid Levels in Mice , 2020, Frontiers in Psychiatry.
[38] Ashley M Sidebottom,et al. IBD Microbial Metabolome: The Good, Bad, and Unknown , 2020, Trends in Endocrinology & Metabolism.
[39] M. Charbonneau,et al. Developing a new class of engineered live bacterial therapeutics to treat human diseases , 2020, Nature Communications.
[40] K. Clément,et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders , 2020, Nature Reviews Gastroenterology & Hepatology.
[41] Julie C. Lumeng,et al. Global chemical effects of the microbiome include new bile-acid conjugations , 2020, Nature.
[42] H. Sokol,et al. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease , 2020, Nature Reviews Gastroenterology & Hepatology.
[43] Laxmi Parida,et al. Human Skin, Oral, and Gut Microbiomes Predict Chronological Age , 2020, mSystems.
[44] Justin J. J. van der Hooft,et al. Mass spectrometry searches using MASST , 2020, Nature Biotechnology.
[45] E. Chang,et al. Intersection of the Gut Microbiome and Circadian Rhythms in Metabolism , 2020, Trends in Endocrinology & Metabolism.
[46] Christine M. Aceves,et al. Reproducible molecular networking of untargeted mass spectrometry data using GNPS , 2019, Nature Protocols.
[47] F. Shanahan,et al. Differences in Fecal Microbiomes and Metabolomes of People With vs Without Irritable Bowel Syndrome and Bile Acid Malabsorption. , 2019, Gastroenterology.
[48] A. Farmer,et al. Critical evaluation of animal models of visceral pain for therapeutics development: A focus on irritable bowel syndrome , 2019, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[49] X. Fang,et al. A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome , 2019, The Journal of clinical investigation.
[50] Manfred von der Ohe,et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial , 2019, The Lancet.
[51] J. Vendrell,et al. Gut microbiota-derived succinate: Friend or foe in human metabolic diseases? , 2019, Reviews in Endocrine and Metabolic Disorders.
[52] R. Haeusler,et al. Bile acids in glucose metabolism and insulin signalling — mechanisms and research needs , 2019, Nature Reviews Endocrinology.
[53] C. Beaudoin,et al. Farnesoid X receptor alpha (FXRα) is a critical actor of the development and pathologies of the male reproductive system , 2019, Cellular and Molecular Life Sciences.
[54] M. Schmulson,et al. Fecal microbiota transplantation in irritable bowel syndrome: A systematic review and meta-analysis , 2019, United European gastroenterology journal.
[55] M. Surette,et al. Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review. , 2019, Gastroenterology.
[56] N. Bray. The microbiota–gut–brain axis , 2019 .
[57] M. Linterman,et al. Heterochronic faecal transplantation boosts gut germinal centres in aged mice , 2019, Nature Communications.
[58] R. Loomba,et al. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications , 2019, Alimentary pharmacology & therapeutics.
[59] Liang Yao,et al. The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis , 2019, Gastroenterology research and practice.
[60] A. Zorzano,et al. SUCNR1 controls an anti-inflammatory program in macrophages to regulate the metabolic response to obesity , 2019, Nature Immunology.
[61] M. Camilleri,et al. Analysis of Fecal Primary Bile Acids Detects Increased Stool Weight and Colonic Transit in Patients With Chronic Functional Diarrhea , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[62] R. Knight,et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease , 2019, Nature Communications.
[63] G. Farrugia,et al. Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS , 2019, Gut.
[64] P. Higgins,et al. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. , 2019, The American journal of gastroenterology.
[65] Jaw-Yuan Wang,et al. Fecal microbiota transplantation: Review and update. , 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.
[66] R. Evans,et al. FXR Regulates Intestinal Cancer Stem Cell Proliferation , 2019, Cell.
[67] Austin D. Swafford,et al. Age- and Sex-Dependent Patterns of Gut Microbial Diversity in Human Adults , 2019, mSystems.
[68] L. Duan,et al. Alterations of Gut Microbiota in Patients With Irritable Bowel Syndrome Based on 16S rRNA-Targeted Sequencing: A Systematic Review , 2019, Clinical and translational gastroenterology.
[69] D. Brenner,et al. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose‐dependent changes with increase in fibrosis stage in patients with biopsy‐proven NAFLD , 2018, Alimentary pharmacology & therapeutics.
[70] Wen-Ting Li,et al. Bile acids induce visceral hypersensitivity via mucosal mast cell–to–nociceptor signaling that involves the farnesoid X receptor/nerve growth factor/transient receptor potential vanilloid 1 axis , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[71] Eric A. Franzosa,et al. Gut microbiome structure and metabolic activity in inflammatory bowel disease , 2018, Nature Microbiology.
[72] P. Moayyedi,et al. Systematic review with meta‐analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome , 2018, Alimentary pharmacology & therapeutics.
[73] P. de Vos,et al. Sex differences in lipid metabolism are affected by presence of the gut microbiota , 2018, Scientific Reports.
[74] S. Aquila,et al. Activated-farnesoid X receptor (FXR) expressed in human sperm alters its fertilising ability. , 2018, Reproduction.
[75] Lingyan Ye,et al. Niacin fine-tunes energy homeostasis through canonical GPR109A signaling , 2018, bioRxiv.
[76] R. Knight,et al. Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism , 2018, Nature Communications.
[77] Luke R. Thompson,et al. Best practices for analysing microbiomes , 2018, Nature Reviews Microbiology.
[78] Weston R. Whitaker,et al. Gut Microbiota-Produced Tryptamine Activates an Epithelial G-Protein-Coupled Receptor to Increase Colonic Secretion. , 2018, Cell host & microbe.
[79] Kathleen A Cronin,et al. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics , 2018, Cancer.
[80] Justine W. Debelius,et al. The gut–liver axis and the intersection with the microbiome , 2018, Nature Reviews Gastroenterology & Hepatology.
[81] V. Sepe,et al. Farnesoid X receptor modulators 2014-present: a patent review , 2018, Expert opinion on therapeutic patents.
[82] A. Rosa,et al. Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson’s Disease , 2018, Molecular Neurobiology.
[83] Rob Knight,et al. Current understanding of the human microbiome , 2018, Nature Medicine.
[84] S. Pluchino,et al. Macrophage-Derived Extracellular Succinate Licenses Neural Stem Cells to Suppress Chronic Neuroinflammation , 2018, Cell stem cell.
[85] D. Chinnapen,et al. Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease , 2018, Journal of Microbiology.
[86] K. Katsanos,et al. Role of bile acids in inflammatory bowel disease , 2018, Annals of gastroenterology.
[87] H. Flint,et al. Specific substrate-driven changes in human faecal microbiota composition contrast with functional redundancy in short-chain fatty acid production , 2017, The ISME Journal.
[88] Jeffrey J. Tabor,et al. Engineering Diagnostic and Therapeutic Gut Bacteria , 2017, Microbiology spectrum.
[89] T. Dinan,et al. Microbiota-related Changes in Bile Acid & Tryptophan Metabolism are Associated with Gastrointestinal Dysfunction in a Mouse Model of Autism , 2017, EBioMedicine.
[90] S. Zeisel,et al. Trimethylamine N-Oxide, the Microbiome, and Heart and Kidney Disease. , 2017, Annual review of nutrition.
[91] E. Hsiao,et al. The Microbiome and Host Behavior. , 2017, Annual review of neuroscience.
[92] M. Nieto‐Sampedro,et al. TUDCA: An Agonist of the Bile Acid Receptor GPBAR1/TGR5 With Anti‐Inflammatory Effects in Microglial Cells , 2017, Journal of cellular physiology.
[93] P. Saha,et al. Hepatic FXR/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice , 2017, Hepatology.
[94] D. Francisci,et al. The Bile Acid Receptor GPBAR1 Regulates the M1/M2 Phenotype of Intestinal Macrophages and Activation of GPBAR1 Rescues Mice from Murine Colitis , 2017, The Journal of Immunology.
[95] R. Knight,et al. Global chemical analysis of biology by mass spectrometry , 2017 .
[96] A. Petrescu,et al. Bile Acid-Mediated Sphingosine-1-Phosphate Receptor 2 Signaling Promotes Neuroinflammation during Hepatic Encephalopathy in Mice , 2017, Front. Cell. Neurosci..
[97] B. Staels,et al. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia and NAFLD. , 2017 .
[98] M. Surette,et al. Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction , 2017, Cell host & microbe.
[99] G. Farrugia,et al. Human-derived gut microbiota modulates colonic secretion in mice by regulating 5-HT3 receptor expression via acetate production. , 2017, American journal of physiology. Gastrointestinal and liver physiology.
[100] J. Chiang,et al. G‐protein‐coupled bile acid receptor plays a key role in bile acid metabolism and fasting‐induced hepatic steatosis in mice , 2017, Hepatology.
[101] C. Gahan,et al. Disease-Associated Changes in Bile Acid Profiles and Links to Altered Gut Microbiota , 2017, Digestive Diseases.
[102] M. Surette,et al. Transplantation of fecal microbiota from patients with irritable bowel syndrome alters gut function and behavior in recipient mice , 2017, Science Translational Medicine.
[103] J. Chiang,et al. Intestinal Farnesoid X Receptor and Takeda G Protein Couple Receptor 5 Signaling in Metabolic Regulation , 2017, Digestive Diseases.
[104] D. Antonopoulos,et al. Mutual reinforcement of pathophysiological host‐microbe interactions in intestinal stasis models , 2017, Physiological reports.
[105] G. Guo,et al. Role of FXR in Liver Inflammation During Nonalcoholic Steatohepatitis , 2017, Current Pharmacology Reports.
[106] P. Kashyap,et al. Irritable bowel syndrome: a gut microbiota-related disorder? , 2017, American journal of physiology. Gastrointestinal and liver physiology.
[107] M. Nieto‐Sampedro,et al. TGFβ Contributes to the Anti-inflammatory Effects of Tauroursodeoxycholic Acid on an Animal Model of Acute Neuroinflammation , 2017, Molecular Neurobiology.
[108] S. Lynch,et al. The Human Intestinal Microbiome in Health and Disease. , 2016, The New England journal of medicine.
[109] F. Shanahan,et al. Unconjugated Bile Acids Influence Expression of Circadian Genes: A Potential Mechanism for Microbe-Host Crosstalk , 2016, PloS one.
[110] Rob Knight,et al. Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease , 2016, Cell.
[111] Timothy K Lu,et al. Microbiome therapeutics - Advances and challenges. , 2016, Advanced drug delivery reviews.
[112] Hanns-Ulrich Marschall,et al. Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism. , 2016, Cell metabolism.
[113] F. Bäckhed,et al. From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites , 2016, Cell.
[114] E. Comelli,et al. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease , 2016, PloS one.
[115] Oluf Pedersen,et al. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials , 2016, Genome Medicine.
[116] P. Bork,et al. Durable coexistence of donor and recipient strains after fecal microbiota transplantation , 2016, Science.
[117] S. Kulling,et al. Age-Related Changes of Plasma Bile Acid Concentrations in Healthy Adults—Results from the Cross-Sectional KarMeN Study , 2016, PloS one.
[118] H. Gaskins,et al. Taurocholic acid metabolism by gut microbes and colon cancer , 2016, Gut microbes.
[119] F. Pattou,et al. Bile Diversion in Roux-en-Y Gastric Bypass Modulates Sodium-Dependent Glucose Intestinal Uptake. , 2016, Cell metabolism.
[120] C. Gahan,et al. Bile Acid Modifications at the Microbe-Host Interface: Potential for Nutraceutical and Pharmaceutical Interventions in Host Health. , 2016, Annual review of food science and technology.
[121] A. Margolles,et al. Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health , 2016, Front. Microbiol..
[122] K. Schoonjans,et al. Bile acid-FXRα pathways regulate male sexual maturation in mice , 2016, Oncotarget.
[123] Matthew McMillin,et al. Bile Acid Signaling Is Involved in the Neurological Decline in a Murine Model of Acute Liver Failure. , 2016, The American journal of pathology.
[124] Dong-Hyun Kim,et al. Gut microbiota lipopolysaccharide accelerates inflamm-aging in mice , 2016, BMC Microbiology.
[125] F. Bäckhed,et al. Microbiota-induced obesity requires farnesoid X receptor , 2016, Gut.
[126] P. Hylemon,et al. Consequences of bile salt biotransformations by intestinal bacteria , 2016, Gut microbes.
[127] William H. Bisson,et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction , 2015, Nature Communications.
[128] Matthew McMillin,et al. TGR5 signaling reduces neuroinflammation during hepatic encephalopathy , 2015, Journal of neurochemistry.
[129] B. Hayee,et al. Systematic review: bile acids and intestinal inflammation‐luminal aggressors or regulators of mucosal defence? , 2015, Alimentary pharmacology & therapeutics.
[130] Rohit Loomba,et al. Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. , 2015, Mayo Clinic proceedings.
[131] R. Carroll,et al. In Vivo Regulation of Colonic Cell Proliferation, Differentiation, Apoptosis, and P27Kip1 by Dietary Fish Oil and Butyrate in Rats , 2015, Cancer Prevention Research.
[132] I. Amit,et al. Host microbiota constantly control maturation and function of microglia in the CNS , 2015, Nature Neuroscience.
[133] J. Sonnenburg,et al. Gut microbes promote colonic serotonin production through an effect of short‐chain fatty acids on enterochromaffin cells , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[134] J. Murabito,et al. Distinct Metabolomic Signatures Are Associated with Longevity in Humans , 2015, Nature Communications.
[135] C. Lozupone,et al. Gut bacteria in children with autism spectrum disorders: challenges and promise of studying how a complex community influences a complex disease , 2015, Microbial ecology in health and disease.
[136] Leo Lahti,et al. Fat, Fiber and Cancer Risk in African Americans and Rural Africans , 2015, Nature Communications.
[137] D. Brenner,et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance , 2015, Nature Medicine.
[138] J. Koenig,et al. Microbial shifts in the aging mouse gut , 2014, Microbiome.
[139] J. Chiang,et al. Bile Acid Signaling in Metabolic Disease and Drug Therapy , 2014, Pharmacological Reviews.
[140] R. Pellicciari,et al. Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands. , 2014, Current topics in medicinal chemistry.
[141] C. Hill,et al. Bacterial bile salt hydrolase in host metabolism: Potential for influencing gastrointestinal microbe-host crosstalk , 2014, Gut microbes.
[142] G. Marceau,et al. Bile acids alter male fertility through G‐protein‐coupled bile acid receptor 1 signaling pathways in mice , 2014, Hepatology.
[143] Matthew McMillin,et al. Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[144] D. Mukherji,et al. Secondary bile acids: an underrecognized cause of colon cancer , 2014, World Journal of Surgical Oncology.
[145] C. Hill,et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut , 2014, Proceedings of the National Academy of Sciences.
[146] J. Tiedje,et al. Revealing the Bacterial Butyrate Synthesis Pathways by Analyzing (Meta)genomic Data , 2014, mBio.
[147] A. Rudensky,et al. Microbial metabolites control gut inflammatory responses , 2014, Proceedings of the National Academy of Sciences.
[148] F. Bäckhed,et al. Microbiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain Neural Circuits , 2014, Cell.
[149] M. Camilleri. Advances in understanding of bile acid diarrhea , 2014, Expert review of gastroenterology & hepatology.
[150] C. Mackay,et al. The role of short-chain fatty acids in health and disease. , 2014, Advances in immunology.
[151] J. Petrosino,et al. Microbiota Modulate Behavioral and Physiological Abnormalities Associated with Neurodevelopmental Disorders , 2013, Cell.
[152] S. Rampelli,et al. Functional metagenomic profiling of intestinal microbiome in extreme ageing , 2013, Aging.
[153] F. Bäckhed,et al. Microbial modulation of energy availability in the colon regulates intestinal transit. , 2013, Cell host & microbe.
[154] Hong Liang,et al. Bile Acids Modulate Signaling by Functional Perturbation of Plasma Membrane Domains* , 2013, The Journal of Biological Chemistry.
[155] L. Brandt,et al. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. , 2013, Gastrointestinal endoscopy.
[156] J. Chiang. Bile acid metabolism and signaling. , 2013, Comprehensive Physiology.
[157] Manuel Serrano,et al. The Hallmarks of Aging , 2013, Cell.
[158] Fredrik H. Karlsson,et al. Gut metagenome in European women with normal, impaired and diabetic glucose control , 2013, Nature.
[159] M. Bohlooly-y,et al. Ageing Fxr Deficient Mice Develop Increased Energy Expenditure, Improved Glucose Control and Liver Damage Resembling NASH , 2013, PloS one.
[160] P. Edwards,et al. Pleiotropic roles of bile acids in metabolism. , 2013, Cell metabolism.
[161] G. Tsujimoto,et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43 , 2013, Nature Communications.
[162] Fei Li,et al. FXR signaling in the enterohepatic system , 2013, Molecular and Cellular Endocrinology.
[163] M. Dapoigny,et al. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota , 2013, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.
[164] F. Bäckhed,et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. , 2013, Cell metabolism.
[165] Wei Sun,et al. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. , 2012, Molecular cell.
[166] H. Flint,et al. Role of the gut microbiota in nutrition and health , 2018, British Medical Journal.
[167] Qiang Feng,et al. A metagenome-wide association study of gut microbiota in type 2 diabetes , 2012, Nature.
[168] D. Sinderen,et al. Gut microbiota composition correlates with diet and health in the elderly , 2012, Nature.
[169] T. Hibi,et al. Bile acids induce monocyte differentiation toward interleukin‐12 hypo‐producing dendritic cells via a TGR5‐dependent pathway , 2012, Immunology.
[170] Rui F. M. Silva,et al. Neuritic growth impairment and cell death by unconjugated bilirubin is mediated by NO and glutamate, modulated by microglia, and prevented by glycoursodeoxycholic acid and interleukin-10 , 2012, Neuropharmacology.
[171] R. D'Hooge,et al. TUDCA, a Bile Acid, Attenuates Amyloid Precursor Protein Processing and Amyloid-β Deposition in APP/PS1 Mice , 2012, Molecular Neurobiology.
[172] P. Neuvonen,et al. Gender, but not CYP7A1 or SLCO1B1 polymorphism, affects the fasting plasma concentrations of bile acids in human beings. , 2012, Basic & clinical pharmacology & toxicology.
[173] P. Deen,et al. The Succinate Receptor as a Novel Therapeutic Target for Oxidative and Metabolic Stress-Related Conditions , 2012, Front. Endocrin..
[174] G. Bifulco,et al. The Bile Acid Receptor GPBAR-1 (TGR5) Modulates Integrity of Intestinal Barrier and Immune Response to Experimental Colitis , 2011, PloS one.
[175] A. Moschetta,et al. Bile acids and colon cancer: Solving the puzzle with nuclear receptors. , 2011, Trends in molecular medicine.
[176] M. Orešič,et al. Farnesoid X Receptor Deficiency Improves Glucose Homeostasis in Mouse Models of Obesity , 2011, Diabetes.
[177] S. Kliewer,et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. , 2011, Cell metabolism.
[178] J. Auwerx,et al. The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. , 2011, Journal of hepatology.
[179] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[180] P. Siersema,et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease , 2011, Gut.
[181] M. Messaoudi,et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects , 2010, British Journal of Nutrition.
[182] Marcus J. Claesson,et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly , 2010, Proceedings of the National Academy of Sciences.
[183] M. Cawthorne,et al. Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids , 2010, FEBS letters.
[184] S. Fiorucci,et al. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders. , 2009, Trends in pharmacological sciences.
[185] J. Auwerx,et al. TGR5-mediated bile acid sensing controls glucose homeostasis. , 2009, Cell metabolism.
[186] W. R. Wikoff,et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites , 2009, Proceedings of the National Academy of Sciences.
[187] Ann M. Thomas,et al. Farnesoid X Receptor Deficiency in Mice Leads to Increased Intestinal Epithelial Cell Proliferation and Tumor Development , 2009, Journal of Pharmacology and Experimental Therapeutics.
[188] T. Wiele,et al. Arabinoxylan‐oligosaccharides (AXOS) affect the protein/carbohydrate fermentation balance and microbial population dynamics of the Simulator of Human Intestinal Microbial Ecosystem , 2008, Microbial biotechnology.
[189] B. Roe,et al. A core gut microbiome in obese and lean twins , 2008, Nature.
[190] A. Moschetta,et al. Nuclear bile acid receptor FXR protects against intestinal tumorigenesis. , 2008, Cancer research.
[191] Masashi Yanagisawa,et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41 , 2008, Proceedings of the National Academy of Sciences.
[192] Yang Li,et al. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. , 2008, Endocrinology.
[193] N. Mitro,et al. The pharmacological exploitation of cholesterol 7alpha-hydroxylase, the key enzyme in bile acid synthesis: from binding resins to chromatin remodelling to reduce plasma cholesterol. , 2007, Pharmacology & therapeutics.
[194] N. Mitro,et al. Age‐related changes in bile acid synthesis and hepatic nuclear receptor expression , 2007, European journal of clinical investigation.
[195] F. Moy,et al. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone. , 2006, Endocrinology.
[196] Folkert Kuipers,et al. The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice* , 2006, Journal of Biological Chemistry.
[197] Ke Ma,et al. Farnesoid X receptor is essential for normal glucose homeostasis. , 2006, The Journal of clinical investigation.
[198] J. Auwerx,et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation , 2006, Nature.
[199] Timothy M Willson,et al. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[200] Ki-Choon Choi,et al. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. , 2005, Endocrinology.
[201] Folkert Kuipers,et al. The Farnesoid X Receptor Modulates Hepatic Carbohydrate Metabolism during the Fasting-Refeeding Transition* , 2005, Journal of Biological Chemistry.
[202] G. Tsujimoto,et al. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. , 2005, Biochemical and biophysical research communications.
[203] R. Sinha,et al. Meat consumption and risk of colorectal cancer. , 2005, JAMA.
[204] S. Joo,et al. Ursodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1β and nitric oxide in rat microglia , 2003, Archives of pharmacal research.
[205] Giovanni Galli,et al. Coordinated Control of Cholesterol Catabolism to Bile Acids and of Gluconeogenesis via a Novel Mechanism of Transcription Regulation Linked to the Fasted-to-fed Cycle* , 2003, Journal of Biological Chemistry.
[206] Grace Guo,et al. The Farnesoid X-receptor Is an Essential Regulator of Cholesterol Homeostasis* , 2003, The Journal of Biological Chemistry.
[207] Ricky W. Johnstone,et al. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.
[208] H. Clevers,et al. APC, Signal transduction and genetic instability in colorectal cancer , 2001, Nature Reviews Cancer.
[209] M. Camilleri. Pathophysiology in irritable bowel syndrome. , 2001, Drug news & perspectives.
[210] J. Dietschy,et al. Gender‐related differences in bile acid and sterol metabolism in outbred CD‐1 mice fed low‐ and high‐cholesterol diets , 1998, Hepatology.
[211] Valentino Bontempo,et al. Branched-chain amino acids. , 2015, Methods in enzymology.
[212] G. Belforte,et al. Simulation of the metabolism and enterohepatic circulation of endogenous deoxycholic acid in humans using a physiologic pharmacokinetic model for bile acid metabolism. , 1987, Gastroenterology.
[213] G. Macfarlane,et al. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. , 1987, Gut.
[214] M. M. Fisher,et al. Sex differences in the bile acid composition of human bile: studies in patients with and without gallstones. , 1973, Canadian Medical Association journal.
[215] T. Midtvedt,et al. Metabolism of cholic acid in germfree animals after the establishment in the intestinal tract of deconjugating and 7 alpha-dehydroxylating bacteria. , 2009, Acta pathologica et microbiologica Scandinavica.
[216] T. Midtvedt,et al. Bile acid transformations by microbial strains belonging to genera found in intestinal contents. , 1967, Acta pathologica et microbiologica Scandinavica.
[217] T. Midtvedt,et al. ISOLATED FECAL MICROORGANISMS CAPABLE OF 7 α-DEHYDROXYLATING BILE ACIDS , 1966, The Journal of experimental medicine.